My biggest question, in the BOM realm, given the proven profound advantage of coupling standard of care with Apabetalone, why isn't BP fighting over themselves to buy us out?  This makes no sense to me.

Regarding the COVID application, I like where they're headed, the fact they aren't doing private placements at less than .85, Eversana, current available data all looking very good.  COVID isn't going anywhere, but I believe it will eventually be manageable to the point where it's no longer considered a serious affliction, not unlike the common flu or cold is today.

I wouldn't look for any meaningful SP movement over the near term.  Maybe a pop tomorrow, but there are plenty of those who will sell into the uptick.  RVX is pretty predictable that way

GLTA